- Previous Close
24.66 - Open
24.53 - Bid 24.36 x 100
- Ask 24.62 x 100
- Day's Range
24.33 - 24.78 - 52 Week Range
22.36 - 31.23 - Volume
45,537 - Avg. Volume
294,396 - Market Cap (intraday)
1.627B - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.02 - Earnings Date Apr 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.37
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
www.glpg.comRecent News: GLPG
View MorePerformance Overview: GLPG
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is AEX-Index (^AEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLPG
View MoreValuation Measures
Market Cap
1.64B
Enterprise Value
-1.90B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.22
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
26.88%
Return on Assets (ttm)
-2.75%
Return on Equity (ttm)
-0.05%
Revenue (ttm)
275.65M
Net Income Avi to Common (ttm)
-1.28M
Diluted EPS (ttm)
-0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
3.12B
Total Debt/Equity (mrq)
0.41%
Levered Free Cash Flow (ttm)
-274.43M